Published in J Acquir Immune Defic Syndr on April 15, 2015
Dysregulation of Systemic and Mucosal Humoral Responses to Microbial and Food Antigens as a Factor Contributing to Microbial Translocation and Chronic Inflammation in HIV-1 Infection. PLoS Pathog (2017) 0.78
The Interplay of Host Immunity, Environment and the Risk of Bacterial Vaginosis and Associated Reproductive Health Outcomes. J Infect Dis (2016) 0.75
Estradiol and progesterone influence on influenza infection and immune response in a mouse model. Am J Reprod Immunol (2017) 0.75
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis (2011) 10.96
The nature of the principal type 1 interferon-producing cells in human blood. Science (1999) 10.90
Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol (2008) 6.17
Glycerol monolaurate prevents mucosal SIV transmission. Nature (2009) 5.02
Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 3.25
Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis (2013) 2.70
Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS (2007) 2.44
The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev (2003) 2.30
Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS (2010) 2.23
Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis (2004) 2.03
Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol (2001) 1.95
Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev (2009) 1.95
Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques. Lab Invest (1992) 1.83
Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms. Endocrinology (2013) 1.81
Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol (2013) 1.77
Secretion of cytokines and chemokines by polarized human epithelial cells from the female reproductive tract. Hum Reprod (2005) 1.63
Tissue inhibitors of metalloproteinases. Genome Biol (2011) 1.62
Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium. Fertil Steril (2003) 1.57
The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception (1999) 1.50
Cutting edge: progesterone regulates IFN-alpha production by plasmacytoid dendritic cells. J Immunol (2008) 1.44
The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS (2012) 1.26
Evaluating the competing risks of HIV acquisition and maternal mortality in Africa: a decision analysis. BJOG (2012) 1.24
Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retroviruses (2012) 1.23
Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. J Acquir Immune Defic Syndr (2014) 1.23
Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev (2012) 1.20
Vaginal langerhans cells nonproductively transporting HIV-1 mediate infection of T cells. J Virol (2011) 1.19
Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs. Contraception (2014) 1.15
Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids (2011) 1.13
Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS (2013) 1.11
Hormonal contraception and risk of cervical infections among HIV-1-seropositive Kenyan women. AIDS (2004) 1.11
Influence of hormonal contraceptives on the immune cells and thickness of human vaginal epithelium. Obstet Gynecol (2003) 1.10
Research gaps in defining the biological link between HIV risk and hormonal contraception. Am J Reprod Immunol (2014) 1.08
Synthetic progestins used in HRT have different glucocorticoid agonist properties. Mol Cell Endocrinol (2005) 1.08
Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells. J Infect Dis (2014) 1.05
The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception (2000) 1.05
Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation. J Infect Dis (2004) 1.04
Comprehensive assessment of sociodemographic and behavioral risk factors for Mycoplasma genitalium infection in women. Sex Transm Dis (2010) 1.01
Progesterone increases the number of Langerhans cells in human vaginal epithelium. Fertil Steril (2001) 0.94
Medroxyprogesterone acetate alters Mycobacterium bovis BCG-induced cytokine production in peripheral blood mononuclear cells of contraceptive users. PLoS One (2011) 0.89
Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate. Contraception (2014) 0.86
Use of hormonal contraceptives and risk of HIV-1 transmission. Lancet Infect Dis (2012) 0.84
Differential glucocorticoid receptor-mediated effects on immunomodulatory gene expression by progestin contraceptives: implications for HIV-1 pathogenesis. Am J Reprod Immunol (2014) 0.83
Immunosuppressive biological mechanisms support reassessment of use of the injectable contraceptive medroxyprogesterone acetate. Endocrinology (2013) 0.80
Flash freezing of Mohs micrographic surgery tissue can minimize freeze artifact and speed slide preparation. Dermatol Surg (2011) 0.80
Injectable contraceptives: a worldwide perspective. J Fam Plann Reprod Health Care (2002) 0.78
Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med (2007) 7.90
Abdominal sacrocolpopexy with Burch colposuspension to reduce urinary stress incontinence. N Engl J Med (2006) 7.42
Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med (2009) 5.58
A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med (2012) 4.59
The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence. Ann Intern Med (2006) 3.93
A midurethral sling to reduce incontinence after vaginal prolapse repair. N Engl J Med (2012) 2.90
Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA (2002) 2.79
Two-year outcomes after sacrocolpopexy with and without burch to prevent stress urinary incontinence. Obstet Gynecol (2008) 2.58
A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes. Obstet Gynecol (2003) 2.57
Global ratings of patient satisfaction and perceptions of improvement with treatment for urinary incontinence: validation of three global patient ratings. Neurourol Urodyn (2006) 2.48
Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women: a randomized controlled trial. JAMA (2003) 2.31
Fecal and urinary incontinence in primiparous women. Obstet Gynecol (2006) 2.28
Vaginal hysterectomy: past, present, and future. Int Urogynecol J (2014) 2.14
Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med (2012) 2.03
Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial. JAMA (2004) 1.97
A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol (2005) 1.94
Incontinence outcomes in women undergoing primary and repeat midurethral sling procedures. Obstet Gynecol (2013) 1.91
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol (2010) 1.85
Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol (2008) 1.85
Prevalence and correlates of fecal incontinence in community-dwelling older adults. J Am Geriatr Soc (2005) 1.84
Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection. J Virol (2009) 1.84
Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms. Endocrinology (2013) 1.81
Incidence and risk factors for fecal incontinence in black and white older adults: a population-based study. J Am Geriatr Soc (2010) 1.79
Anal incontinence in women presenting for gynecologic care: prevalence, risk factors, and impact upon quality of life. Am J Obstet Gynecol (2005) 1.74
Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. Obstet Gynecol (2002) 1.73
Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstet Gynecol (2014) 1.70
Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med (2008) 1.68
Urodynamics, the supine empty bladder stress test, and incontinence severity. Neurourol Urodyn (2010) 1.66
Colpocleisis: a review. Int Urogynecol J Pelvic Floor Dysfunct (2005) 1.65
The effect of urodynamic testing on clinical diagnosis, treatment plan and outcomes in women undergoing stress urinary incontinence surgery. J Urol (2012) 1.64
The role of preoperative urodynamic testing in stress-continent women undergoing sacrocolpopexy: the Colpopexy and Urinary Reduction Efforts (CARE) randomized surgical trial. Int Urogynecol J Pelvic Floor Dysfunct (2008) 1.64
Prevalence and correlates of nocturia in community-dwelling older adults. J Am Geriatr Soc (2010) 1.62
Urinary bacteria in adult women with urgency urinary incontinence. Int Urogynecol J (2014) 1.61
Effectiveness of treatment strategies of some women with pelvic inflammatory disease: a randomized trial. Obstet Gynecol (2005) 1.60
Pelvic organ prolapse. Obstet Gynecol (2005) 1.53
The "costs" of urinary incontinence for women. Obstet Gynecol (2006) 1.52
Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J Immunol (2002) 1.52
A model for predicting the risk of de novo stress urinary incontinence in women undergoing pelvic organ prolapse surgery. Obstet Gynecol (2014) 1.52
Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial. Obstet Gynecol (2004) 1.52
Obesity and urinary incontinence: epidemiology and clinical research update. J Urol (2009) 1.52
Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008. J Urol (2011) 1.50
Urinary incontinence in the 12-month postpartum period. Obstet Gynecol (2003) 1.50
Factors impacting quality of life in women with fecal incontinence. Dis Colon Rectum (2010) 1.49
Changes in urinary and fecal incontinence symptoms with weight loss surgery in morbidly obese women. Obstet Gynecol (2007) 1.49
Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause (2015) 1.47
Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease? Am J Obstet Gynecol (2008) 1.45
Design of the Value of Urodynamic Evaluation (ValUE) trial: A non-inferiority randomized trial of preoperative urodynamic investigations. Contemp Clin Trials (2009) 1.44
Prolapse and incontinence surgery in older women. J Urol (2008) 1.39
Process for development of multicenter urodynamic studies. Urology (2007) 1.37
Population based study of incidence and predictors of urinary incontinence in black and white older adults. J Urol (2008) 1.37
Effect of weight loss on urinary incontinence in overweight and obese women: results at 12 and 18 months. J Urol (2010) 1.31
Can known risk factors explain racial differences in the occurrence of bacterial vaginosis? J Natl Med Assoc (2003) 1.30
Fragile X-related protein FXR1P regulates proinflammatory cytokine tumor necrosis factor expression at the post-transcriptional level. J Biol Chem (2004) 1.26
Why women douche and why they may or may not stop. Sex Transm Dis (2003) 1.26
Incontinence in older women. JAMA (2010) 1.20
Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol (2004) 1.20
Early HIV-1 target cells in human vaginal and ectocervical mucosa. Am J Reprod Immunol (2010) 1.19
Obesity and pelvic floor disorders: a systematic review. Obstet Gynecol (2008) 1.17
Role of the Orc6 protein in origin recognition complex-dependent DNA binding and replication in Drosophila melanogaster. Mol Cell Biol (2007) 1.16
Cervicovaginal lamina propria lymphocytes: phenotypic characterization and their importance in cytotoxic T-lymphocyte responses to simian immunodeficiency virus SIVmac251. J Virol (2002) 1.15
Racial differences in pelvic anatomy by magnetic resonance imaging. Obstet Gynecol (2008) 1.15
Chlamydia antibodies, chlamydia heat shock protein, and adverse sequelae after pelvic inflammatory disease: the PID Evaluation and Clinical Health (PEACH) Study. Sex Transm Dis (2008) 1.13
Pelvic organ support among primiparous women in the first year after childbirth. Int Urogynecol J Pelvic Floor Dysfunct (2009) 1.10
Patient satisfaction with stress incontinence surgery. Neurourol Urodyn (2010) 1.09
One-year outcomes of tension-free vaginal tape (TVT) mid-urethral slings in overweight and obese women. Int Urogynecol J Pelvic Floor Dysfunct (2009) 1.09
Douching, pelvic inflammatory disease, and incident gonococcal and chlamydial genital infection in a cohort of high-risk women. Am J Epidemiol (2005) 1.09
The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog (2013) 1.07
Intraabdominal pressure changes associated with lifting: implications for postoperative activity restrictions. Am J Obstet Gynecol (2008) 1.07
Regret, satisfaction, and symptom improvement: analysis of the impact of partial colpocleisis for the management of severe pelvic organ prolapse. Am J Obstet Gynecol (2005) 1.07
Correlation between levator ani muscle injuries on magnetic resonance imaging and fecal incontinence, pelvic organ prolapse, and urinary incontinence in primiparous women. Am J Obstet Gynecol (2010) 1.06
Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J Reprod Immunol (2009) 1.06
Predictors of outcome in the behavioral treatment of urinary incontinence in women. Obstet Gynecol (2003) 1.05
Effect of weight change on natural history of pelvic organ prolapse. Obstet Gynecol (2009) 1.05
Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial. Contemp Clin Trials (2011) 1.04
Predictors of success with postoperative voiding trials after a mid urethral sling procedure. J Urol (2007) 1.03
Correlates of urinary, fecal, and dual incontinence in older African-American and white men and women. J Am Geriatr Soc (2007) 1.03
Risk factors for fecal and urinary incontinence after childbirth: the childbirth and pelvic symptoms study. Am J Gastroenterol (2007) 1.03
Measuring outcomes in urogynecological surgery: "perspective is everything". Int Urogynecol J (2012) 1.03
Wet/dry mapping: using citizen scientists to monitor the extent of perennial surface flow in dryland regions. Environ Manage (2011) 1.02
Variability of bacterial vaginosis over 6- to 12-month intervals. Sex Transm Dis (2006) 1.02
The questionnaire for urinary incontinence diagnosis (QUID): validity and responsiveness to change in women undergoing non-surgical therapies for treatment of stress predominant urinary incontinence. Neurourol Urodyn (2010) 1.01
Magnetic resonance assessment of pelvic anatomy and pelvic floor disorders after childbirth. Int Urogynecol J Pelvic Floor Dysfunct (2008) 1.01
Challenges in designing a pragmatic clinical trial: the mixed incontinence -- medical or surgical approach (MIMOSA) trial experience. Clin Trials (2009) 1.01
Improving urinary incontinence in overweight and obese women through modest weight loss. Obstet Gynecol (2010) 1.00
Treatment success of retropubic and transobturator mid urethral slings at 24 months. J Urol (2012) 1.00
Bladder symptoms 1 year after abdominal sacrocolpopexy with and without Burch colposuspension in women without preoperative stress incontinence symptoms. Am J Obstet Gynecol (2007) 0.99
Sexual function before and after sacrocolpopexy for pelvic organ prolapse. Am J Obstet Gynecol (2007) 0.98
Management strategies for abnormal early pregnancy: a cost-effectiveness analysis. J Reprod Med (2005) 0.98
Delivery method, anal sphincter tears and fecal incontinence: new information on a persistent problem. Curr Opin Obstet Gynecol (2007) 0.98
Associated factors and the impact of fecal incontinence in women with urge urinary incontinence: from the Urinary Incontinence Treatment Network's Behavior Enhances Drug Reduction of Incontinence study. Am J Obstet Gynecol (2009) 0.97
Reproducibility of dynamic MR imaging pelvic measurements: a multi-institutional study. Radiology (2008) 0.96
The role of vaginal mesh procedures in pelvic organ prolapse surgery in view of complication risk. Obstet Gynecol Int (2013) 0.95
Utility of preoperative endometrial assessment in asymptomatic women undergoing hysterectomy for pelvic floor dysfunction. Int Urogynecol J (2012) 0.94
The effect of age on stress and urgency urinary incontinence outcomes in women undergoing primary midurethral sling. Int Urogynecol J (2014) 0.93
Spanish language translation of pelvic floor disorders instruments. Int Urogynecol J Pelvic Floor Dysfunct (2007) 0.92
Weight loss improves fecal incontinence severity in overweight and obese women with urinary incontinence. Int Urogynecol J (2011) 0.92
Specific and nonspecific membrane-binding determinants cooperate in targeting phosphatidylinositol transfer protein beta-isoform to the mammalian trans-Golgi network. Mol Biol Cell (2006) 0.92